Gubra is seeking a dedicated and experienced Department Manager to lead our Molecular Pharmacology department. The ideal candidate will possess proven leadership abilities and a passion for managing and developing teams, along with a background in molecular pharmacology and drug discovery.
The Molecular Pharmacology department plays an important role in supporting Gubra's peptide drug discovery initiatives by developing in vitro assays (cellular, non-cellular, enzymatic, etc.) to characterize novel peptide drug candidates. We are committed to delivering high-quality potency data and continuously integrating cutting-edge in vitro technologies to support Gubra's innovative and technological projects. Our team comprises of 5 scientists and 5 laboratory technicians who work collaboratively across the entire drug discovery value chain, engaging in both in-house and partnered projects.
In recent years, we have successfully developed highly automated workflows to enhance our drug screening platform, facilitating high-throughput peptide synthesis and data generation. This advancement has been achieved through close collaboration with the Chemistry and AI departments. The Molecular Pharmacology department is part of the larger In vitro & Pharmaceutical Research area, which includes Chemistry, Preformulation, Bioanalysis, Drug Formulation and Biomarker Assay.
As Department Manager your tasks include
Your competencies
As a person you
Please apply no later than May 5, 2024, by uploading your motivated cover letter and resume on our website. Please note that applications will be evaluated on a rolling basis. If you have questions about the position, please contact Director of In vitro & Pharmaceutical Research Anja Mosekjær Bengtsson at anb@gubra.dk.
About Gubra
Gubra is an ambitious contract research organisation (CRO) and biotech company striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the fight for a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight the ongoing climate and biodiversity crises.
Gubra’s activities are focused on the early stages of drug development and are organised in two highly synergistic business areas: CRO Services and Discovery & Partnerships (D&P). We generate our revenue by performing research for life science companies as well as by partnering projects from our discovery and development pipeline.
Our therapeutic focus is within metabolic and fibrotic diseases, and we specialize in in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. In addition, we offer a full palette of advanced transcriptomics. Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit into a non-clinical candidate ready for development. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market.
People are our greatest asset, and our team consists of +220 employees all located in Hørsholm, Denmark. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by entrepreneurial drive, scientific curiosity, and teamwork – we join forces!